(Chondroitin 200mg + Collagen Peptide (Type I, II, V, X) 200mg + Sodium Hyaluronate 75mg + Vitamin C 50mg + Rosehip Extract 10mg Tablets) Multi-component formulations combining collagen peptides, chondroitin, sodium hyaluronate, vitamin C and botanical extract in a solid oral dosage form Many ingredients are combined in this formulation that are present at various particle sizes, bulk densities, moisture contents, and behavior in processing, so the blending process, or process, becomes a fundamental part of the product development. For companies looking to extend their range of specialty formulations, this combination can be made part of a quality assured PCD Pharma Franchise.
The required formula consists of five main ingredients, chondroitin and collagen peptide by 200mg, sodium hyaluronate by 75mg, vitamin C by 50mg and rosehip extract by 10mg. In this respect, with such a large discrepancy in weight, it is necessary to carry out intentional mixing and distribution of ingredients.
In Development During production, powder characteristics such as particle size, bulk density, flowability, hygroscopicity and compatibility are measured for each material. For example, botanical extracts and collagen peptides exhibit different powder behavior to mineral and polymeric ingredients. The amount of rosehip extract is smaller so distribution must be more uniform.
The excipients are selected by the desired characteristics of the tablets and based on compatibility of the functional and active ingredients. The formulation goal is to produce a stable powder blend that can be tableted, with uniform composition and physical properties.
The 10mg rosehip extract and 50mg vitamin C have to be incorporated in a formulation with much larger quantities of the other ingredients. If used, a controlled premix recipe can lead to better dispersion of these small-quantity ingredients across the entire blend.
Staged blending or geometric dilution are techniques that might be employed in formulation development, depending on the properties of the material. The order of mixing is defined in order to avoid segregation and to keep the most representative distribution of the components.
The physical properties of the blend can also be affected by the powder form of sodium hyaluronate, and it's on moisture sensitivity. Hence, good environment conditions and handling procedures can be added into the manufacture.
Representative testing of blended material is achieved by testing samples from different points across the batch. This will ensure the process is producing a homogenous blend before compression.
Once mixed, the formulation should have adequate processing properties for tableting. Powder flow, compressibility, bulk density and moisture content can all affect die filling and the uniformity of tablet weights.
The compression process is designed to provide the correct tablet hardness, thickness, friability, and mechanical strength without unduly affecting the physical properties of the formulation. Compression force and speed of the machine can be optimized during process development.
The presence of collagen peptides and other high load ingredients can impact on the volume of the tablet and tablet compaction behavior. It may be necessary to modify the excipient system to facilitate adequate tablet formation and ensure uniform processing.
Some in-process controls are tablet weight, hardness, thickness, visual appearances, and friability. In-process controls help to recognize process variations occurring during manufacture and assurance of uniform finished-product quality.
A plan for analysis needs to be written because the multiple ingredients of the composition means varying tests are likely to be needed. Finished-product testing may involve identification and assay of the relevant components, dosing-unit uniformity, physical testing, moisture testing and more depending on the formulation.
Analytical control adequate for Vitamin C must be implemented since this compound is sensitive to the environment during storage. Depending on the product specification, Rosehip extract must be valued based on extract specifications or marker compounds.
. Collagen peptide and chondroitin may need to be tested for identity and/or quantitative analysis if raw material specifications and finished product specifications so dictate. Sodium hyaluronate can also be tested for identity using relevant quality standards.
The testing must be appropriately qualified/validated for its intended use. Good testing allows a product to be released, monitors stability, and enables a comparison between manufacturing lots.
Moisture control may be an important consideration for a formulation with collagen peptides, botanical extract, sodium hyaluronate and a high percentage of powders. Powder flow and physical stability can be affected by humidity in the environment during manufacturing and storage.
Stability studies can track one or more parameters like appearance, integrity of tablets, assay, moisture, dissolution where appropriate, or any other quality characteristic, at predetermined periods.
Pharmaceutical packaging shall be selected according to the stability profile of the formulation, and blister packs or strips, bottles, or other appropriate systems of pharmaceutical packaging shall be tested for moisture and compatibility.
Likewise, packaging development considers all aspects of container-closure integrity, including seal performance, protection during transit and correct labeling. Storage requirements are based on data, not presumption.
Chondroitin 200mg + Collagen Peptide (Type I, II, V, X) 200mg + Sodium Hyaluronate 75mg + Vitamin C 50mg + Rosehip Extract 10mg Tablets are a technically complex multi-ingredient solid dosage form. The wide variety in the ingredient quantities make premixing, blend uniformity, powder handling, compression, analysis, and moisture content critical aspects of product development.
This product line can be targeted as part of a new specialized tablet category for companies establishing a diversified PCD Pharma Franchise portfolio, which has tightly controlled manufacturing specifications and recorded quality procedures.
Each process - from initial raw-material qualification and staged blending to compression, finished-product testing, stability testing, and protective packaging - plays an important role in ensuring product consistency. A systematic development process ensures the composition and physical properties of the tablets remain within specification.
Chondroitin, collagen peptides, sodium hyaluronate, vitamin C and rosehip extract tablets with formulation, manufacturing, quality and stability details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech